Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 7/20 | 0.65 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.57 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.57 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.57 |
| ▸ | F10 | P00742 | 1/20 | 0.54 |
| ▸ | LTA4H | P09960 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17894553 | 0.90 | MAOB (0.61) | F2 | |
| SCHEMBL4987199 | 0.89 | LTA4H (0.66) | LTA4HMEN1CYP1A2CYP2C19KMT2A | |
| SCHEMBL23566298 | 0.86 | PARP10 (0.56) | F2PRSS1PRSS2PRSS3LTA4H | |
| SCHEMBL27663855 | 0.86 | MRGPRX4 (0.52) | F2F10LTA4H | |
| Trifluoroacetic Acid SCHEMBL17894407 | 0.81 | RXRA (0.55) | F2LTA4H | |
| SCHEMBL17894484 | 0.80 | MAOB (0.57) | F2PRSS1PRSS2PRSS3LTA4H | |
| SCHEMBL27683541 | 0.80 | PARP10 (0.57) | F2PRSS1PRSS2PRSS3LTA4H | |
| Trifluoroacetic Acid SCHEMBL17894392 | 0.79 | LTA4H (0.61) | LTA4HMEN1CYP1A2CYP2C19KMT2A | |
| SCHEMBL4028152 | 0.79 | MAPK1 (0.58) | F2F10LTA4HMEN1KMT2A | |
| SCHEMBL14543821 | 0.79 | F2 (1.00) | F2PRSS1PRSS2PRSS3F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210309641-A1 | AMIDINES AND AMIDINE ANALOGS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION ANTIBIOTICS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2021-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210309641-A1 | AMIDINES AND AMIDINE ANALOGS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION ANTIBIOTICS | PAM, AMPD1, AMPD3 | F2 1488/4885PRSS1 652/4885PRSS2 1318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.